Gayton v. McCoy

521 F. Supp. 2d 841, 74 Fed. R. Serv. 1111, 2007 U.S. Dist. LEXIS 77174, 2007 WL 3037248
CourtDistrict Court, C.D. Illinois
DecidedOctober 17, 2007
Docket04-CV-1354
StatusPublished

This text of 521 F. Supp. 2d 841 (Gayton v. McCoy) is published on Counsel Stack Legal Research, covering District Court, C.D. Illinois primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gayton v. McCoy, 521 F. Supp. 2d 841, 74 Fed. R. Serv. 1111, 2007 U.S. Dist. LEXIS 77174, 2007 WL 3037248 (C.D. Ill. 2007).

Opinion

OPINION

BYRON G. CUDMORE, United States Magistrate Judge.

Defendants Radcliffe et al. have filed a Motion to Bar Opinions of Corey Wein-stein, M.D., Pertaining to Cause of Death (d/e 121). The other defendants have joined in the motion, (d/e 123). After careful consideration of the parties’ submissions, and for the reasons detailed below, the Court concludes that the motion should be granted.

I. Legal Standard

The admissibility of expert testimony is governed by Federal Rule of Evidence 702 and Daubert. Under this framework, courts determine whether the expert testimony is both relevant and reliable. It is a three-step analysis: the witness must be qualified “as an expert by knowledge, skill, experience, training or education.” Fed.R.Evid. 702; the expert’s reasoning or methodology underlying the testimony must be scientifically reliable, Daubert, 509 U.S. at 592-93, 113 S.Ct. 2786; and the testimony must assist the trier of fact to understand the evidence or to determine a fact in issue. Fed.R.Evid. 702.

Ervin v. Johnson & Johnson, Inc., 492 F.3d 901, 904 (7th Cir.2007). Plaintiff beats the burden of establishing the admissibility of Dr. Weinstein’s expert testimony by a preponderance of the evidence. Fed.R.Evid. 702 Advisory Committee Notes, 2000 Amendments (the admissibility of expert testimony is governed by Rule 104(a), which puts the burden on the proponent to establish admissibility by preponderance).

In Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 593-95, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993), the Supreme Court set forth some potentially appropriate factors to consider when assessing the reliability of expert testimony, including whether the theory can or has been tested; whether the theory has been subjected to peer review and publication; the rate of error of the theory when applied; and, whether the theory is generally accepted. These factors are not definitive nor do they “all necessarily apply even in every instance in which the reliability of *844 scientific testimony is challenged.” Kumho Tire Co., Ltd. v. Carmichael, 526 U.S. 137, 151, 119 S.Ct. 1167, 143 L.Ed.2d 238 (1999); Bourelle v. Crown Equipment Corp., 220 F.3d 532, 536 n. 8 (7th Cir.2000)(“there is no requirement that the district judge consider each one of ... [Daubert] ‘guideposts’ when making an admissibility ruling under Fed.R.Evid. 702”). The polestar is “ensuring] the reliability and relevancy of expert testimony .... [,] to make certain that an expert, whether basing testimony upon professional studies or personal experience, employs in the courtroom the same level of intellectual rigor that characterizes the practice of an expert in the relevant field.” Kumho, 526 U.S. at 152,119 S.Ct. 1167.

Federal Rule of Evidence 702, amended in response to Daubert, provides:

If scientific, technical, or other specialized knowledge will assist the trier of fact to understand the evidence or to determine a fact in issue, a witness qualified as an expert by knowledge, skill, experience, training, or education, may testify thereto in the form of an opinion or otherwise, if (1) the testimony is based upon sufficient facts or data, (2) the testimony is the product of rehable principles and methods, and (3) the witness has applied the principles and methods reliably to the facts of the case. 1

“A court is expected to reject ‘any subjective belief or speculation.’ ” Ammons v. Aramark Uniform Serv., 368 F.3d 809, 816 (7th Cir.2004)(quoted cites omitted). However, determinations on admissibility do not supplant the adversarial process. “Shaky” expert testimony may nevertheless be admissible, assailable by its opponents through cross-examination and the introduction of contradicting evidence. Daubert, 509 U.S. at 596, 113 S.Ct. 2786(“Vigorous cross-examination, presentation of contrary evidence, and careful instruction on the burden of proof are the traditional and appropriate means of attacking shaky but admissible evidence.”) Nor can the court exclude expert testimony because “the court believes one version of [competing] facts and not the other.” Fed.R.Evid. Advisory Committee Notes, 2000 Amendments (recognizing that “experts sometimes reach different conclusions based on competing version of the facts.”). “The focus, ... must be solely on principles and methodology, not on the conclusions that they generate.” Daubert, 509 U.S. at 595, 113 S.Ct. 2786.

II. Dr. Weinstein’s Opinions on Ms. Taylor’s Cause of Death

A. Dr. Weinstein’s Preliminary Report 2

Dr. Weinstein’s “preliminary report” of February 1, 2006 states in relevant part:

10. Ms. India Taylor suffered from serious chronic illnesses. At the time of her 10/15/2003 incarceration in the PCJ 3 she [Ms. Taylor] had been prescribed four medications for her cardiovascular illness by her private physician. Her medicine regimen was complex and sophisticated: Furosemide, Acetazolamide, Metolazine and Coreg. Heroin withdrawal usually causes elevations of heart rate and blood pressure, both of which *845 would make cardiovascular disease worse. Had Ms. Taylor’s medication not been interrupted and instead been provided, as is routine and standard in jail medical care; and had her heroin withdrawal been treated as was demanded by PCJ protocol, then it is likely that the lethal event on 10/17/2003 would have been prevented. (2/1/06 preliminary report, p. 2).

B. Dr. Weinstein’s Supplemental Report

Dr. Weinstein’s supplemental report of December 14, 2006 states in relevant part:

6.... On October 15, 2003, prescriptions from Walgreen’s Pharmacy were Meto-lazone, Coreg, Lasix and Acetazolamide. The three diuretic medication and alpha-beta blocker regimen is a sophisticated treatment program for serious cardiac disease ...

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Daubert v. Merrell Dow Pharmaceuticals, Inc.
509 U.S. 579 (Supreme Court, 1993)
General Electric Co. v. Joiner
522 U.S. 136 (Supreme Court, 1997)
Kumho Tire Co. v. Carmichael
526 U.S. 137 (Supreme Court, 1999)
Bass v. Wallenstein
769 F.2d 1173 (First Circuit, 1985)
Shirley Carroll v. Otis Elevator Company
896 F.2d 210 (Seventh Circuit, 1990)
Raymond Rosen v. Ciba-Geigy Corporation
78 F.3d 316 (Seventh Circuit, 1996)
Richard Walker v. Soo Line Railroad Company
208 F.3d 581 (Seventh Circuit, 2000)
Mark A. Smith v. Ford Motor Company
215 F.3d 713 (Seventh Circuit, 2000)
Clyde Ammons v. Aramark Uniform Services, Inc.
368 F.3d 809 (Seventh Circuit, 2004)
Ervin v. Johnson & Johnson, Inc.
492 F.3d 901 (Seventh Circuit, 2007)
O'CONNER v. Commonwealth Edison Co.
807 F. Supp. 1376 (C.D. Illinois, 1992)
Cooper, Robert E. v. Nelson & Company
211 F.3d 1008 (Seventh Circuit, 2000)
Wintz v. Northrop Corp.
110 F.3d 508 (Seventh Circuit, 1997)

Cite This Page — Counsel Stack

Bluebook (online)
521 F. Supp. 2d 841, 74 Fed. R. Serv. 1111, 2007 U.S. Dist. LEXIS 77174, 2007 WL 3037248, Counsel Stack Legal Research, https://law.counselstack.com/opinion/gayton-v-mccoy-ilcd-2007.